You are here

Tecentriq

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

Endpoints

clinical trials

Flag link:

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

Fierce Pharma

clinical trials

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Endpoints

Flag link:

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

Endpoints

clinical trials

Flag link:

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Fierce Pharma

Flag link:

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Fierce Pharma

Flag link:

4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't

4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't

Motley Fool

HER-2 postive breast cancer

multiple sclerosis

Flag link:

3 Big Pharma Companies With the Best Pipelines

3 Big Pharma Companies With the Best Pipelines

Motley Fool

Flag link:

Should Merck, BMS Fear Roche's Drug Becoming The I-O King?

Should Merck, BMS Fear Roche's Drug Becoming The I-O King?

Seeking Alpha

Bristol-Myers Squibb

immuno-oncology

Flag link:

Roche says Phase II trial supports twin treatment for kidney cancer

Roche says Phase II trial supports twin treatment for kidney cancer

Yahoo/Reuters

Flag link:

Checkpoint inhibitors set to face off in bladder cancer

Checkpoint inhibitors set to face off in bladder cancer

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Roche cancer drug taking bite out of Bristol's Opdivo

Roche cancer drug taking bite out of Bristol's Opdivo

Yahoo/Reuters

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

Market Realist

Bristol-Myers Squibb

Flag link:

Roche flags early success for Tecentriq combos, hustles into PhIIIs

Roche flags early success for Tecentriq combos, hustles into PhIIIs

Endpoints

clinical trials

Flag link:

Roche's lung cancer drug wins U.S. approval

Roche's lung cancer drug wins U.S. approval

Yahoo/Reuters

non-small cell lung cancer

Flag link:

Roche lung cancer drug success adds to pressure on Bristol

Roche lung cancer drug success adds to pressure on Bristol

Yahoo/Reuters

Flag link:

3 Critical FDA Decisions You Can't Afford to Miss

3 Critical FDA Decisions You Can't Afford to Miss

Motley Fool

Vertex Pharmaceuticals

Flag link:

Roche's Tecentriq ready to compete in lung cancer

Roche's Tecentriq ready to compete in lung cancer

BioPharma Dive

non-small cell lung cancer

Flag link:

Epizyme partners with Roche to test cancer drug combo

Epizyme partners with Roche to test cancer drug combo

BioPharma Dive

PDL-1 inhibitors

diffuse large B-cell lymphoma

Flag link: